Clinical Trials Browser

Phase 3 × INDUSTRY × penpulimab × Clear all

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

296 enrolled 1 FDA

Nasopharyngeal Carcinoma

NCT05862337 2023-05-17

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular